Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Phase Modulators Based on High Mobility Ambipolar ReSe2 Field-Effect Transistors.

Pradhan NR, Garcia C, Isenberg B, Rhodes D, Feng S, Memaran S, Xin Y, McCreary A, Walker ARH, Raeliarijaona A, Terrones H, Terrones M, McGill S, Balicas L.

Sci Rep. 2018 Aug 24;8(1):12745. doi: 10.1038/s41598-018-30969-7.

2.

Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.

Newman-Tancredi A, Varney MA, McCreary AC.

Neurochem Res. 2018 May;43(5):1035-1046. doi: 10.1007/s11064-018-2514-y. Epub 2018 Mar 23.

PMID:
29572645
3.

Intricate Resonant Raman Response in Anisotropic ReS2.

McCreary A, Simpson JR, Wang Y, Rhodes D, Fujisawa K, Balicas L, Dubey M, Crespi VH, Terrones M, Hight Walker AR.

Nano Lett. 2017 Oct 11;17(10):5897-5907. doi: 10.1021/acs.nanolett.7b01463. Epub 2017 Sep 12.

PMID:
28820602
4.

Optical identification of sulfur vacancies: Bound excitons at the edges of monolayer tungsten disulfide.

Carozo V, Wang Y, Fujisawa K, Carvalho BR, McCreary A, Feng S, Lin Z, Zhou C, Perea-López N, Elías AL, Kabius B, Crespi VH, Terrones M.

Sci Adv. 2017 Apr 28;3(4):e1602813. doi: 10.1126/sciadv.1602813. eCollection 2017 Apr.

5.

Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

Huot P, Sgambato-Faure V, Fox SH, McCreary AC.

ACS Chem Neurosci. 2017 May 17;8(5):973-986. doi: 10.1021/acschemneuro.6b00440. Epub 2017 May 5. Review.

PMID:
28460160
6.

Frequency-Dependent Modulation of Dopamine Release by Nicotine and Dopamine D1 Receptor Ligands: An In Vitro Fast Cyclic Voltammetry Study in Rat Striatum.

Goutier W, Lowry JP, McCreary AC, O'Connor JJ.

Neurochem Res. 2016 May;41(5):945-50. doi: 10.1007/s11064-015-1786-8. Epub 2016 Mar 15.

PMID:
26975318
7.

Effects of Uniaxial and Biaxial Strain on Few-Layered Terrace Structures of MoS₂ Grown by Vapor Transport.

McCreary A, Ghosh R, Amani M, Wang J, Duerloo KA, Sharma A, Jarvis K, Reed EJ, Dongare AM, Banerjee SK, Terrones M, Namburu RR, Dubey M.

ACS Nano. 2016 Mar 22;10(3):3186-97. doi: 10.1021/acsnano.5b04550. Epub 2016 Feb 23.

PMID:
26881920
8.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9.

PMID:
26777281
9.

Metal to Insulator Quantum-Phase Transition in Few-Layered ReS₂.

Pradhan NR, McCreary A, Rhodes D, Lu Z, Feng S, Manousakis E, Smirnov D, Namburu R, Dubey M, Walker AR, Terrones H, Terrones M, Dobrosavljevic V, Balicas L.

Nano Lett. 2015 Dec 9;15(12):8377-84. doi: 10.1021/acs.nanolett.5b04100. Epub 2015 Nov 30.

PMID:
26599563
10.

Ultrasensitive gas detection of large-area boron-doped graphene.

Lv R, Chen G, Li Q, McCreary A, Botello-Méndez A, Morozov SV, Liang L, Declerck X, Perea-López N, Cullen DA, Feng S, Elías AL, Cruz-Silva R, Fujisawa K, Endo M, Kang F, Charlier JC, Meunier V, Pan M, Harutyunyan AR, Novoselov KS, Terrones M.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14527-32. doi: 10.1073/pnas.1505993112. Epub 2015 Nov 2. Erratum in: Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E406.

11.

Psychostimulants: Basic and Clinical Pharmacology.

McCreary AC, Müller CP, Filip M.

Int Rev Neurobiol. 2015;120:41-83. doi: 10.1016/bs.irn.2015.02.008. Epub 2015 Mar 25. Review.

PMID:
26070753
12.

Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.

McCreary AC, Newman-Tancredi A.

Curr Pharm Des. 2015;21(26):3725-31. Review.

PMID:
26044980
13.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
14.

Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation following nicotine withdrawal in rats.

Zaniewska M, Alenina N, Wydra K, Fröhler S, Kuśmider M, McCreary AC, Chen W, Bader M, Filip M.

J Neurochem. 2015 Aug;134(4):704-16. doi: 10.1111/jnc.13192. Epub 2015 Jun 26.

15.

Context-controlled nicotine-induced changes in the labeling of serotonin (5-HT)2A and 5-HT2C receptors in the rat brain.

Zaniewska M, McCreary AC, Wydra K, Faron-Górecka A, Filip M.

Pharmacol Rep. 2015 Jun;67(3):451-9. doi: 10.1016/j.pharep.2014.11.002. Epub 2014 Nov 24.

PMID:
25933953
16.

Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.

Danysz W, Flik G, McCreary A, Tober C, Dimpfel W, Bizot JC, Kostrzewa R, Brown RW, Jatzke CC, Greco S, Jenssen AK, Parsons CG.

J Neural Transm (Vienna). 2015 Sep;122(9):1221-38. doi: 10.1007/s00702-015-1392-6. Epub 2015 Mar 22.

PMID:
25796190
17.

The effect of nicotine induced behavioral sensitization on dopamine D1 receptor pharmacology: An in vivo and ex vivo study in the rat.

Goutier W, O'Connor JJ, Lowry JP, McCreary AC.

Eur Neuropsychopharmacol. 2015 Jun;25(6):933-43. doi: 10.1016/j.euroneuro.2015.02.008. Epub 2015 Mar 3.

PMID:
25795518
18.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
19.

Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.

Goutier W, Kloeze M, McCreary AC.

Addict Biol. 2016 Mar;21(2):234-41. doi: 10.1111/adb.12190. Epub 2014 Oct 13.

PMID:
25307867
20.

The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.

Papathanou M, Jenner P, Iravani M, Jackson M, Stockwell K, Strang I, Zeng BY, McCreary AC, Rose S.

Eur J Pharmacol. 2014 Oct 15;741:304-10. doi: 10.1016/j.ejphar.2014.08.004. Epub 2014 Aug 23.

PMID:
25160743
21.

Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.

Burke MV, Nocjar C, Sonneborn AJ, McCreary AC, Pehek EA.

J Neurochem. 2014 Nov;131(4):432-43. doi: 10.1111/jnc.12842. Epub 2014 Aug 21.

22.

The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.

Goutier W, Kloeze MB, McCreary AC.

Addict Biol. 2015 Mar;20(2):248-58. doi: 10.1111/adb.12108. Epub 2013 Nov 20.

PMID:
24251901
23.

Serotonin2C receptors and drug addiction: focus on cocaine.

Devroye C, Filip M, Przegaliński E, McCreary AC, Spampinato U.

Exp Brain Res. 2013 Oct;230(4):537-45. doi: 10.1007/s00221-013-3593-2. Epub 2013 Jun 8. Review.

PMID:
23748692
24.

Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.

Kruk M, Miszkiel J, McCreary AC, Przegaliński E, Filip M, Biała G.

Pharmacol Rep. 2012;64(6):1316-25.

25.

Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.

Papathanou M, van der Laan R, Jenner P, Rose S, McCreary AC.

Mov Disord. 2013 Jul;28(8):1072-9. doi: 10.1002/mds.25218. Epub 2012 Nov 2.

PMID:
23125107
26.

A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar rats.

de Bruin NM, McCreary AC, van Loevezijn A, de Vries TJ, Venhorst J, van Drimmelen M, Kruse CG.

Behav Brain Res. 2013 Jan 1;236(1):157-65. doi: 10.1016/j.bbr.2012.08.048. Epub 2012 Sep 4.

PMID:
22974550
27.

Assessment of ropinirole as a reinforcer in rhesus monkeys.

Freeman KB, Heal DJ, McCreary AC, Woolverton WL.

Drug Alcohol Depend. 2012 Sep 1;125(1-2):173-7. doi: 10.1016/j.drugalcdep.2012.04.001. Epub 2012 Apr 28.

PMID:
22546848
28.

Measurement of the neutron radius of 208Pb through parity violation in electron scattering.

Abrahamyan S, Ahmed Z, Albataineh H, Aniol K, Armstrong DS, Armstrong W, Averett T, Babineau B, Barbieri A, Bellini V, Beminiwattha R, Benesch J, Benmokhtar F, Bielarski T, Boeglin W, Camsonne A, Canan M, Carter P, Cates GD, Chen C, Chen JP, Hen O, Cusanno F, Dalton MM, De Leo R, de Jager K, Deconinck W, Decowski P, Deng X, Deur A, Dutta D, Etile A, Flay D, Franklin GB, Friend M, Frullani S, Fuchey E, Garibaldi F, Gasser E, Gilman R, Giusa A, Glamazdin A, Gomez J, Grames J, Gu C, Hansen O, Hansknecht J, Higinbotham DW, Holmes RS, Holmstrom T, Horowitz CJ, Hoskins J, Huang J, Hyde CE, Itard F, Jen CM, Jensen E, Jin G, Johnston S, Kelleher A, Kliakhandler K, King PM, Kowalski S, Kumar KS, Leacock J, Leckey J 4th, Lee JH, LeRose JJ, Lindgren R, Liyanage N, Lubinsky N, Mammei J, Mammoliti F, Margaziotis DJ, Markowitz P, McCreary A, McNulty D, Mercado L, Meziani ZE, Michaels RW, Mihovilovic M, Muangma N, Muñoz-Camacho C, Nanda S, Nelyubin V, Nuruzzaman N, Oh Y, Palmer A, Parno D, Paschke KD, Phillips SK, Poelker B, Pomatsalyuk R, Posik M, Puckett AJ, Quinn B, Rakhman A, Reimer PE, Riordan S, Rogan P, Ron G, Russo G, Saenboonruang K, Saha A, Sawatzky B, Shahinyan A, Silwal R, Sirca S, Slifer K, Solvignon P, Souder PA, Sperduto ML, Subedi R, Suleiman R, Sulkosky V, Sutera CM, Tobias WA, Troth W, Urciuoli GM, Waidyawansa B, Wang D, Wexler J, Wilson R, Wojtsekhowski B, Yan X, Yao H, Ye Y, Ye Z, Yim V, Zana L, Zhan X, Zhang J, Zhang Y, Zheng X, Zhu P; PREX Collaboration.

Phys Rev Lett. 2012 Mar 16;108(11):112502. Epub 2012 Mar 15.

PMID:
22540469
29.

Pharmacological and genetic interventions in serotonin (5-HT)(2C) receptors to alter drug abuse and dependence processes.

Filip M, Spampinato U, McCreary AC, Przegaliński E.

Brain Res. 2012 Oct 2;1476:132-53. doi: 10.1016/j.brainres.2012.03.035. Epub 2012 Mar 23. Review.

PMID:
22494568
30.

Effects of the histamine H3 receptor antagonist ABT-239 on acute and repeated nicotine locomotor responses in rats.

Miszkiel J, Kruk M, McCreary AC, Przegaliński E, Biała G, Filip M.

Pharmacol Rep. 2011;63(6):1553-9.

31.

The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats.

Adamczyk P, Miszkiel J, McCreary AC, Filip M, Papp M, Przegaliński E.

Brain Res. 2012 Mar 20;1444:45-54. doi: 10.1016/j.brainres.2012.01.030. Epub 2012 Jan 20.

PMID:
22325096
32.

Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.

Iravani MM, McCreary AC, Jenner P.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S123-5. doi: 10.1016/S1353-8020(11)70038-4. Review.

PMID:
22166408
33.

Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Jenner P, McCreary AC, Scheller DK.

J Neural Transm (Vienna). 2011 Dec;118(12):1691-702. doi: 10.1007/s00702-011-0703-9. Epub 2011 Sep 1. Review.

PMID:
21881838
34.

Institutional, individual, and socio-cultural domains of partnerships: a typology of USDA Forest Service recreation partners.

Seekamp E, Cerveny LK, McCreary A.

Environ Manage. 2011 Sep;48(3):615-30. doi: 10.1007/s00267-011-9695-3. Epub 2011 Jun 28.

PMID:
21710222
35.

Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats.

Papathanou M, Rose S, McCreary A, Jenner P.

Eur J Neurosci. 2011 Jun;33(12):2247-54. doi: 10.1111/j.1460-9568.2011.07704.x. Epub 2011 May 25.

PMID:
21615558
36.

In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.

Bétry C, Etiévant A, Lambás-Señas L, McCreary AC, Haddjeri N.

Synapse. 2011 Oct;65(10):1042-51. doi: 10.1002/syn.20936. Epub 2011 May 3.

PMID:
21446003
37.

The 5-HT₆ serotonin receptor antagonist SB-271046 attenuates the development and expression of nicotine-induced locomotor sensitisation in Wistar rats.

de Bruin NM, Kloeze BM, McCreary AC.

Neuropharmacology. 2011 Sep;61(3):451-7. doi: 10.1016/j.neuropharm.2011.01.045. Epub 2011 Feb 15.

PMID:
21329711
38.

Effects of serotonin (5-HT)6 receptor ligands on responding for cocaine reward and seeking in rats.

Fijał K, Pachuta A, McCreary AC, Wydra K, Nowak E, Papp M, Bieńkowski P, Kotlińska J, Filip M.

Pharmacol Rep. 2010 Nov-Dec;62(6):1005-14.

39.

Serotonergic involvement in methamphetamine-induced locomotor activity: a detailed pharmacological study.

Steed E, Jones CA, McCreary AC.

Behav Brain Res. 2011 Jun 20;220(1):9-19. doi: 10.1016/j.bbr.2011.01.026. Epub 2011 Jan 22.

PMID:
21262272
40.

NK3 receptors mediate an increase in firing rate of midbrain dopamine neurons of the rat and the guinea pig.

Werkman TR, McCreary AC, Kruse CG, Wadman WJ.

Synapse. 2011 Aug;65(8):814-26. doi: 10.1002/syn.20908. Epub 2011 Mar 21.

PMID:
21218451
41.

The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.

Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P.

Exp Neurol. 2010 Dec;226(2):320-7. doi: 10.1016/j.expneurol.2010.09.007. Epub 2010 Sep 16.

PMID:
20843474
42.

Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats.

Zayara AE, McIver G, Valdivia PN, Lominac KD, McCreary AC, Szumlinski KK.

Psychopharmacology (Berl). 2011 Feb;213(2-3):321-35. doi: 10.1007/s00213-010-1996-3. Epub 2010 Sep 3.

43.

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.

Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P.

Mov Disord. 2010 Oct 15;25(13):2059-66. doi: 10.1002/mds.23249.

PMID:
20721904
44.

An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.

Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG, McCreary AC.

Eur Neuropsychopharmacol. 2010 Aug;20(8):582-93. doi: 10.1016/j.euroneuro.2010.03.001.

PMID:
20434890
45.

Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment.

Zaniewska M, McCreary AC, Wydra K, Filip M.

Synapse. 2010 Jul;64(7):511-9. doi: 10.1002/syn.20756.

PMID:
20196140
46.

Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal.

Zaniewska M, McCreary AC, Wydra K, Filip M.

Neuropharmacology. 2010 Jun;58(7):1140-6. doi: 10.1016/j.neuropharm.2010.02.006. Epub 2010 Feb 11.

PMID:
20153341
47.

Development and application of an LC-MS/MS method for measuring the effect of (partial) agonists on cAMP accumulation in vitro.

Goutier W, Spaans PA, van der Neut MA, McCreary AC, Reinders JH.

J Neurosci Methods. 2010 Apr 30;188(1):24-31. doi: 10.1016/j.jneumeth.2010.01.027. Epub 2010 Feb 1.

PMID:
20122962
48.

Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism.

McCreary AC, Jones CA.

Curr Pharm Des. 2010;16(5):516-21. Review.

PMID:
19909230
49.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14.

PMID:
19828876
50.

Supplemental Content

Loading ...
Support Center